Why this market is moving now
- Medicare Part D began covering select GLP-1s for obesity on July 1, 2026, through the Bridge program.
- Lilly's US volume rose 50% in Q4 2025 while realized prices fell 7%.
- About one in eight US adults reported taking a GLP-1 drug in late 2025.
Key figures
Each figure names the source it came from. Open the source list below to read the quoted line.
| Figure | Value | Year | Source |
|---|---|---|---|
| Novo Nordisk's Wegovy sales in the US were DKK 51,015 million in 2025, up 11% in Danish kroner. | 51,015 DKK million | 2025 | Novo Nordisk |
| Novo Nordisk's global Wegovy sales were DKK 79,106 million in 2025, up 36% in Danish kroner. | 79,106 DKK million | 2025 | Novo Nordisk |
| Eli Lilly's US Zepbound revenue was $4.2 billion in the fourth quarter of 2025, up 122% from the year before. | 4.2 USD billion | 2025 | Eli Lilly and Company |
| Eli Lilly's worldwide Mounjaro revenue was $7.4 billion in the fourth quarter of 2025, with $4.1 billion of it in the US. | 7.4 USD billion | 2025 | Eli Lilly and Company |
| Lilly's total US revenue rose 43% to $12.9 billion in the fourth quarter of 2025, on 50% higher volume and 7% lower realized prices. | 12.9 USD billion | 2025 | Eli Lilly and Company |
| 40.3% of US adults had obesity in August 2021 to August 2023. | 40.3 % | 2023 | CDC National Center for Health Statistics |
| 12% of US adults said they were currently taking a GLP-1 drug in a KFF poll fielded October 27 to November 2, 2025. | 12 % | 2025 | KFF |
| Under the Medicare GLP-1 Bridge, manufacturers supply eligible GLP-1s at a net price of $245 per month, and enrollees pay a $50 monthly copay. | 245 USD per month (net price) | 2026 | KFF |
Sources and method
The figures on this page come from the public sources listed below. Read how we work.
- Novo Nordisk: Financial report for the period 1 January 2025 to 31 December 2025 (2026-02-03)
Quoted lines
- Figure 1
Sales of Wegovy® increased by 11% measured in Danish kroner and by 16% at CER to DKK 51,015 million
- Figure 2
Wegovy® sales increased by 36% measured in Danish kroner and by 41% at CER to DKK 79,106 million.
- Figure 1
- Eli Lilly and Company: Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance (2026-02-04)
Quoted lines
- Figure 3
U.S. Zepbound revenue increased 122% to $4.2 billion, compared with $1.9 billion in Q4 2024
- Figure 4
worldwide Mounjaro revenue increased 110% to $7.4 billion. U.S. revenue was $4.1 billion, an increase of 57%
- Figure 5
Revenue in the U.S. increased 43% to $12.9 billion, driven by a 50% increase in volume
- Figure 3
- CDC National Center for Health Statistics: Obesity and Severe Obesity Prevalence in Adults: United States, August 2021–August 2023 (2024-09-24)
Quoted lines
- Figure 6
the prevalence of obesity in adults was 40.3%
- Figure 6
- KFF: Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford (2025-11-14)
Quoted lines
- Figure 7
About one in eight adults (12%) say that they are currently taking a GLP-1 drug
- Figure 7
- KFF: What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge (2026-05-11)
Quoted lines
- Figure 8
Manufacturers have agreed to provide eligible GLP-1s under the Bridge program at a net price of $245 per month supply.
- Figure 8
Companies to watch
Novo Nordisk
Maker of Wegovy; reported DKK 51,015 million of US Wegovy sales in 2025.
Eli Lilly
Maker of Zepbound and Mounjaro; US Zepbound revenue was $4.2 billion in Q4 2025.
What the full report covers
- 01Executive summary
The answer in one page: size, direction and what moves it - 02Market definition and scope
What is in and out of the United States market - 03Market size, 2021 to 2025
Historical series and growth rates - 04Outlook to 2031
Base, low and high scenarios with stated assumptions - 05Rules, policy and deadlines
Regulation and programmes that change demand - 06Drivers and barriers
What accelerates or slows adoption, by customer segment - 07Prices, costs and margins
Unit economics where public data allows - 08Competitive landscape
8 to 12 company profiles with recent moves - 09Opportunities and risks
For new entrants, suppliers and investors - 10Method and sources
Every assumption and source, listed
Included with the full report
- PDF report, 40 to 60 pages
- Excel data pack
- Ready-to-use charts
- Method note and assumptions
- Written to order in 5 working days
Frequently asked questions
How big is the US Wegovy market?
Novo Nordisk reported DKK 51,015 million of Wegovy sales in the US in 2025, up 11% in Danish kroner, in its full-year 2025 financial report.
How much does Zepbound earn in the US?
Eli Lilly's Q4 2025 earnings release says US Zepbound revenue was $4.2 billion in the fourth quarter of 2025, up 122% from Q4 2024.
What share of US adults have obesity?
The CDC's National Center for Health Statistics reported that 40.3% of US adults had obesity between August 2021 and August 2023.
How many Americans take GLP-1 drugs?
A KFF poll fielded October 27 to November 2, 2025 found 12% of US adults said they were currently taking a GLP-1 drug.
Does Medicare cover GLP-1 drugs for obesity?
KFF reports CMS began covering select GLP-1s for obesity in Part D on July 1, 2026, through a Bridge program. The net price is $245 a month and enrollees pay $50.
Who are the main GLP-1 obesity drug makers?
Novo Nordisk (Wegovy) and Eli Lilly (Zepbound and Mounjaro). Novo reported DKK 51,015 million of US Wegovy sales in 2025; Lilly's US Zepbound revenue was $4.2 billion in Q4 2025.
Free sample
Get a free sample of this report
We send the table of contents, two sample chapters and the method note, usually within one working day. You owe us nothing for asking.
- Full table of contents
- Two sample chapters
- Method note and data outline